Improving the tolerability of osimertinib by identifying its toxic limit.
Bram C AgemaG D Marijn VeermanChristi M J SteendamDaan A C LanserTim PreijersCor van der LeestBirgit C P KochAnne-Marie C DingemansRon H J MathijssenStijn L W KoolenPublished in: Therapeutic advances in medical oncology (2022)
Osimertinib exposure is highly correlated with the occurrence of severe toxicity. To optimize tolerability, patients above the toxic limit concentration of 259 ng/mL could benefit from a preventive dose reduction, without fear for diminished effectiveness.
Keyphrases
- small cell lung cancer
- end stage renal disease
- advanced non small cell lung cancer
- open label
- epidermal growth factor receptor
- ejection fraction
- chronic kidney disease
- newly diagnosed
- systematic review
- randomized controlled trial
- peritoneal dialysis
- risk assessment
- clinical trial
- double blind
- early onset
- patient reported outcomes
- placebo controlled
- patient reported